ASH Clinical News Hematology Pipeline Update: Drug Updates from the | Page 4

FEATURES

ASH/FDA Joint Symposium on Late-Breaking Drug
Approvals: Looking into the Future of Myeloma Treatment
At the 2015 ASH Annual Meeting, the U.S. Food and Drug
Administration (FDA) sponsored a session reviewing drugs
that received FDA approval in November 2015 – a month
that saw an unprecedented three new agents added to
the myeloma toolbox: daratumumab, ixazomib, and elotuzumab. The agents’ FDA product-reviewers discussed )ѡ